Dr. Sougioultzoglou has spent more than 15 years as a practicing neurosurgeon and biotech entrepreneur. He received a B.S. in Biomedical Engineering, an M.A. in Medical Sciences (Neurosciences), and an M.D. from Boston University before training as a neurosurgeon at New York Presbyterian Hospital & Memorial Sloan Kettering Cancer Center.

He also trained as a pre-and post-doctoral research fellow at Harvard Medical School, Tufts University School of Medicine, and Rockefeller University.

Dr. Curran is an Associate Attending of Pediatrics at Memorial Sloan Kettering Cancer Center and Associate Professor of Pediatrics at Weil Cornell Medical School. Dr. Curran primary focus is on the treatment of pediatric and adolescent/young adult patients with blood cancers including leukemia within MSK’s Pediatric Stem Cell Transplantation and Cellular Therapies Service. He is both the clinical and research lead for all pediatric investigational and commercial cellular therapies at MSK with a focus on the clinical translation of novel cell therapy products for patients who fail to respond to standard therapeutic approaches.

In addition, Dr. Curran is the Director of the Immune Effector Cell Program (IEC) at MSK responsible for center-wide regulation on the use of cellular therapies. Dr. Curran received his B.S from Villanova University and an M.D. from Georgetown University School of Medicine.

He did his pediatric residency training at Tufts Medical Center, and his hematology-oncology fellowship at MSK before joining the MSK faculty in 2011.

Dr. Marie Bleakley is a pediatric hematologist-oncologist who specializes in hematopoietic (blood-forming) stem cell transplantation and T cell immunotherapy for patients with leukemia and other blood cancers. Her research goal is to develop novel therapies that can optimize the cancer-fighting power of immune T cells while reducing a potentially dangerous side effect known as graft-vs.-host disease, or GVHD. Dr. Bleakley and her team have already pioneered one novel transplantation approach that selectively removes donor T cells that might cause GVHD. They are also genetically engineering T cell therapies that target unique markers to kill a patient’s cancer cells even more effectively.

Dr. Mehta has more than 25 years of experience in regulatory affairs and drug development. He is currently the Chief Technical and Regulatory Officer at Anthos, a biotechnology company in Cambridge, Mass. He previously held senior positions at numerous pharmaceutical and biotechnology companies, including Merck, Shire, Baxalta, Imclone and Bristol-Myers Squibb. He has an extensive track record of global approvals of important therapeutic products including Adynovate®, Vonvendi® and Obizur® (Hemophilia); Keytruda® (Oncology); Elaprase®, Vpriv®, Firazyr® (Orphan); and Erbitux® (Oncology). Dr. Mehta received a B. Tech from the Indian Institute of Technology, Bombay; an M.S. in Chemical Engineering from Colorado State University; and a Ph.D. in Chemical and Biochemical Engineering from Rutgers University.

Dr. Holland is a world-renowned physician-scientist who combines compassionate patient care with exacting laboratory research to discover more effective treatments for brain tumors. He is Professor of Neurological Surgery and the Director of the Nancy and Buster Alvord Brain Tumor Center at the University of Washington School of Medicine, and the SVP of the Human Biology Division of Fred Hutch. As a neurosurgeon, Dr. Holland specializes in caring for patients with glioblastomas, aggressive cancers that are the most common malignant brain tumors in adults. In the laboratory, Dr. Holland has developed important mouse models of brain cancer; he also studies the environment immediately surrounding tumor cells to learn how that “neighborhood” influences tumor formation and growth.

Prior to Fred Hutch, Dr. Holland spent over a decade at Memorial Sloan Kettering Cancer Center. He received his B.S. in Chemistry from Miami University (Ohio), a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago, and an M.D. from Stanford University.

He completed post-doctoral fellowships at Stanford in the lab of Nobel laureate Paul Berg, and at the NIH in the lab of Nobel laureate Harold Varmus. He completed his neurosurgery residency at UCLA.

Brings over 30 years of global biopharma experience, merging science and business. Currently CEO of VarmX, a Netherlands-based biotech focused on bleeding disorders, he previously led Anthos as CEO and held senior roles at J&J, Novartis, and Baxter. His expertise spans company growth, fundraising, licensing, commercialization, and advisory roles with BIO, MIT, Roivant Sciences, and Agent Capital.

Mr. Glasspool holds a B.A. in Politics and International Relations from Staffordshire University, a Diploma in Business Administration from Oxford Brookes University, and completed postgraduate studies in Clinical Pharmacology, Development, and Regulation at Tufts University.

Mr. Jacobson, a corporate and securities partner, has more than 25 years of experience on mergers and acquisitions, private equity, venture capital and capital markets transactions. Until the end of 2025 Mr. Jacobson was a partner at Baker McKenzie; previously, he was a partner at Ropes & Gray, King & Spalding, and Freshfields Bruckhaus Deringer.

Mr. Jacobson was named “Stand-Out Lawyer” by Thomson Reuters in 2022. He received a B.A. in American Studies from Stanford University and a J.D. from University of California, College of the Law, San Francisco (formerly UC Hastings).

Mr. Argyropoulos has over 25 years of experience in corporate finance and investment banking. He serves as the Chief Financial Officer of Performance Shipping Inc. and is also the founder of Seaborne Capital Advisors, an Athens, Greece-based financial advisory firm focused on the shipping and maritime industries. Prior to those roles, Mr. Argyropoulos led numerous financial transactions as a Senior Vice President at Jefferies & Co and as a Partner at Cantor Fitzgerald L.P.

He received a B.A. in Economics from Deree College, Athens; and an M.B.A. in Finance from Bentley College in Waltham, Mass.

Dr. Daniyan is a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) caring for patients with leukemia. He is also a member of MSK’s Cellular Therapeutics Center working to develop next generation CAR T cell therapy and has invented several technologies currently in development to treat cancer. He received a B.S. in Chemistry and Biology from Butler University and an M.D. from the University of Miami School of Medicine.

He completed his internal medicine residency at New York-Presbyterian/Weill Cornell, followed by an oncology fellowship at MSK, where he has been on the faculty since 2017.

Dr. Lee is a physician-scientist and Associate Professor-in-Residence at the David Geffen School of Medicine at UCLA, where he cares for patients with advanced prostate and bladder cancer. Dr. Lee also leads a federally funded basic and translational research laboratory within the UCLA Jonsson Comprehensive Cancer Center. He received an A.B. with highest honors in Biochemical Sciences from Harvard University and an M.D. from the Geisel School of Medicine at Dartmouth.

He completed his clinical training in internal medicine at Boston Medical Center and Specialty Training and Advanced Research (STAR) fellowship in medical oncology at UCLA where he also obtained a Ph.D. from the Molecular Biology Institute under the mentorship of Dr. Owen Witte.

Dr. Sougioultzoglou has spent more than 15 years as a practicing neurosurgeon and biotech entrepreneur. He received a B.S. in Biomedical Engineering, an M.A. in Medical Sciences (Neurosciences), and an M.D. from Boston University before training as a neurosurgeon at New York Presbyterian Hospital & Memorial Sloan Kettering Cancer Center.

He also trained as a pre-and post-doctoral research fellow at Harvard Medical School, Tufts University School of Medicine, and Rockefeller University.